TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02129400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon pro Anaesthesia 100 % (V/V)
Description: Xenon-gas inhalation of indicated concentrations during indicated time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aer medicinalis Linde 100%
Study: NCT00567294

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed education
Description: Mailed education materials on osteoporosis and medication use over a 1-year period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone coaching program for patients
Description: A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone coaching program for patients
Description: A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence alert program for doctors
Description: Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
Study: NCT04906291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste use
Description: Brushing three times a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste use
Description: Brushing three times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste use
Description: Brushing three times a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste use
Description: Brushing three times a day
Study: NCT02974517

Intervention type: DEVICE
Intervention: EmbryoScope®
Description: The intervention is EmbryoScope® versus conventional incubators.

Intervention type: DEVICE
Intervention: EmbryoScope®
Description: The intervention is EmbryoScope® versus conventional incubators.
Study: NCT00764647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program for family caregivers of frail elders
Description: Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
Study: NCT02818569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Oral form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Oral form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Saline Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Saline Placebo
Study: NCT01695902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosert-20
Study: NCT01481766

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: 6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: 6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
Study: NCT01695902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Study: NCT04554979

Intervention type: DRUG
Intervention: Hydroxychloroquine Pill
Description: hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started

Intervention type: DRUG
Intervention: Hydroxychloroquine Pill
Description: hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
Study: NCT01074112

Intervention type: DEVICE
Intervention: EFAST exam
Description: Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs

Intervention type: DEVICE
Intervention: Pelvic Ultrasound
Description: Ultrasound view of the pelvis. including the bladder and uterus

Intervention type: PROCEDURE
Intervention: Ultrasound Guided Vascular Access
Description: Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.

Intervention type: DEVICE
Intervention: Focused Ultrasound Scan
Description: Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.

Intervention type: DEVICE
Intervention: Focused Ultrasound Scan
Description: Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.

Intervention type: DEVICE
Intervention: Focused Ultrasound Scan
Description: Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.

Intervention type: DEVICE
Intervention: Focused Ultrasound Scan
Description: Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.

Intervention type: DEVICE
Intervention: Cardiac Ultrasound
Description: Ultrasound views of the heart

Intervention type: DEVICE
Intervention: Cardiac Ultrasound
Description: Ultrasound views of the heart

Intervention type: DEVICE
Intervention: Cardiac Ultrasound
Description: Ultrasound views of the heart

Intervention type: DEVICE
Intervention: Cardiac Ultrasound
Description: Ultrasound views of the heart
Study: NCT01154790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: 6 subjects: study drug 2 subjects: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 subjects: study drug 2 subjects: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 6 subjects: study drug 2 subjects: placebo
Study: NCT01063868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol extended release (ER)
Description: 100, 150, 200, 250 mg twice daily for 52 weeks
Study: NCT05565508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hasson's technique for laparoscopic access in group b
Description: Hasson's technique for laparoscopic access in group b
Study: NCT02230137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message arm
Description: Text message sent before each injection of insulin
Study: NCT01063868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone controlled release (CR)
Description: 20, 30, 40, 50 mg twice daily for 52 weeks
Study: NCT01481766

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary counseling
Description: Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
Study: NCT00911222

Intervention type: OTHER
Intervention: non-interventional
Description: non-interventional
Study: NCT03506113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gram stain-guided antibiotic choice
Description: The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
Study: NCT01964534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-007
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Study: NCT01964534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² IV /30min (day 1, day 8, day 15)
Study: NCT01831050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Description: Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
Study: NCT01964534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simplified LV5FU2
Description: Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
Study: NCT02695264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000 recording
Study: NCT03844646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Intermittent use of a continuous glucose monitor (CGM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietitian
Description: Monthly meetings with a dietitian

Intervention type: OTHER
Group type: OTHER
Intervention: Dietitian
Description: Monthly meetings with a dietitian
Study: NCT01949506

Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study: NCT00130598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)
Description: control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast.
Study: NCT01835587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
Study: NCT02639143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT02664558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ubenimex

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03506113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines-based antibiotics choice
Description: Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
Study: NCT01287767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A multidimensional support program
Description: Counseling, education and problem-solving in support group, ad hoc counseling
Study: NCT03622216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradanicline
Description: Three different doses over the course of the study
Study: NCT00910338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFMT with Extracorporeal Biofeedback
Description: Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~* Twice a week for the first 4 weeks~* Once a week for the next 8 weeks
Study: NCT00147446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Stress Management
Description: Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List Control
Description: Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
Study: NCT00795314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Tartrate
Description: Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
Study: NCT01897402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Test Vaccine
Description: NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US Licensed Vaccine
Description: Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
Study: NCT03622216

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bradanicline
Description: Three different doses over the course of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo for Bradanicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Bradanicline
Study: NCT03820206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cesarean section
Description: Lower segement transverse cesarean section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: Lower segement transverse cesarean section
Study: NCT03935685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine (Remeron)
Description: Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
Study: NCT05104086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound elastography
Description: strain ratio and resistivity index
Study: NCT04674995

Intervention type: PROCEDURE
Intervention: Stent placement
Description: All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
Study: NCT01815905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile program for occupational and speech therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation therapy
Study: NCT01596296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcervical foley catheter
Description: 16 French foley catheter insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone 10mg
Description: Dinoprostone vaginal insertion